Pharmacology of Drugs for Alzheimer’s Disease

Introduction/Overview

Alzheimer’s disease (AD) represents the most common form of dementia, characterized by progressive cognitive decline, memory impairment, and functional loss. The therapeutic landscape has expanded over recent decades, encompassing symptomatic agents and disease-modifying treatments. Understanding the pharmacological principles that govern these agents is essential for clinicians, pharmacists, and researchers who manage or study AD patients. This monograph aims to provide a detailed examination of the pharmacology of drugs approved for AD, with emphasis on mechanism of action, pharmacokinetics, therapeutic indications, safety profile, drug interactions, and special patient populations.

Learning objectives:

• Identify the principal drug classes used in AD treatment and describe their chemical structures.
• Explain the pharmacodynamic mechanisms that underlie cholinesterase inhibition and NMDA antagonism.
• Summarize key pharmacokinetic parameters influencing dosing regimens in elderly patients.
• Recognize common adverse effects and serious safety concerns associated with AD therapeutics.
• Apply knowledge of drug interactions and special considerations to optimize therapy in vulnerable populations.

Classification

Symptomatic Agents

Symptomatic therapy for AD is primarily divided into two pharmacologic classes: cholinesterase inhibitors (ChEIs) and the N-methyl-D-aspartate (NMDA) receptor antagonist. ChEIs include donepezil, rivastigmine, and galantamine. These agents are structurally diverse but share a common functional goal of enhancing cholinergic neurotransmission. Rivastigmine is a carbamate derivative, whereas donepezil and galantamine belong to the butyrylcholinesterase inhibitor family.

Memantine, the sole NMDA antagonist approved for moderate to severe AD, possesses a low‑affinity, voltage‑dependent blockade of the glutamate receptor, thereby mitigating excitotoxic neuronal injury.

Disease‑Modifying Therapies

Recent advances have introduced monoclonal antibodies targeting amyloid‑β (Aβ) aggregates. Aducanumab, lecanemab, and donanemab are the most prominent examples, each engineered to bind distinct Aβ conformations and facilitate microglial clearance. These agents are categorized as biologic disease‑modifying drugs and represent a paradigm shift from purely symptomatic management.

Other Investigational Agents

Several pharmacologic strategies remain under investigation, including tau aggregation inhibitors, neuroinflammation modulators, and synaptic plasticity enhancers. While not yet approved, these agents illustrate the evolving therapeutic landscape and underscore the importance of staying current with emerging evidence.

Mechanism of Action

Cholinesterase Inhibitors

Acetylcholine (ACh) is a key neurotransmitter involved in memory and cognition. In AD, loss of cholinergic neurons leads to reduced ACh levels. ChEIs inhibit the hydrolysis of ACh by acetylcholinesterase (AChE), thereby increasing synaptic availability. Donepezil binds reversibly to the catalytic triad of AChE, forming a transient carbamate ester that impedes enzymatic activity. Rivastigmine forms a covalent carbamate linkage with AChE, resulting in a longer duration of action. Galantamine exerts dual action by inhibiting AChE and modulating nicotinic ACh receptors, potentially enhancing synaptic plasticity.

NMDA Antagonist – Memantine

Glutamate-mediated excitotoxicity contributes to neuronal death in AD. Memantine binds to the open channel of the NMDA receptor, acting as a low‑affinity, uncompetitive antagonist. This binding is voltage‑dependent, allowing normal physiological activation while preventing excessive calcium influx during pathological overstimulation. Consequently, memantine preserves neuronal integrity without disrupting basal neurotransmission.

Amyloid‑β Targeting Antibodies

Aducanumab, lecanemab, and donanemab bind specific conformations of Aβ fibrils or oligomers. Their Fc regions engage microglial Fcγ receptors, promoting phagocytic clearance of amyloid deposits. This process reduces amyloid plaque burden, potentially slowing neurodegeneration. The precise downstream signaling pathways remain an active area of research, with emphasis on complement activation and inflammatory modulation.

Pharmacokinetics

Donepezil

Absorption: Oral bioavailability approximates 80 %. Peak plasma concentration (C_max) occurs within 3–4 h. Distribution: Extensive tissue penetration with a volume of distribution (V_d) of ~200 L. Metabolism: Primarily hepatic via cytochrome P450 2D6 and 3A4. Excretion: Renal elimination of unchanged drug and metabolites (~30 %). Half‑life (t_1/2): 70 h, permitting once‑daily dosing. Dose adjustments are not routinely required for mild hepatic impairment; however, caution is advised in severe hepatic disease.

Rivastigmine

Absorption: Oral bioavailability ~50 % when administered as a transdermal patch; 50–60 % when taken orally. Peak C_max achieved after 2–4 h. Distribution: V_d ~1.5 L/kg. Metabolism: Hydrolysis via pseudo‑cholinesterase and CYP3A4. Excretion: 70 % renal, 30 % fecal. t_1/2: 1.5–2 h for oral, 7–9 h for transdermal. The transdermal route mitigates gastrointestinal adverse events.

Galantamine

Absorption: Oral bioavailability ~60 %. Peak C_max occurs 1–2 h post‑dose. Distribution: V_d 5–6 L/kg. Metabolism: Hepatic via CYP2D6 and CYP3A4 to active metabolites. Excretion: 50–70 % renal. t_1/2: 5 h. Dosing frequency: Twice daily; dose escalation is common to minimize side effects.

Memantine

Absorption: Oral bioavailability ~60 %. Peak C_max within 1 h. Distribution: V_d 3–4 L/kg. Metabolism: Minimal hepatic metabolism; predominantly renal clearance. Excretion: 90 % unchanged in urine. t_1/2: 60–70 h. The long half‑life permits once‑daily administration, with a gradual titration schedule to reach 20 mg bid.

Aducanumab

Administration: Intravenous infusion over 60–90 min. Distribution: Large molecular size limits blood‑brain barrier penetration; however, active transport mechanisms facilitate central nervous system exposure. Metabolism: Proteolytic degradation via the reticuloendothelial system. Excretion: Primarily via hepatic clearance. t_1/2: 1–2 days. Dose: 10 mg/kg every 4 weeks, with adjustments based on imaging biomarkers.

Lecanemab

Similar to aducanumab, lecanemab is administered intravenously. Dose: 10 mg/kg every 2 weeks. Pharmacokinetic parameters are analogous, with a half‑life of ~10 days.

Donanemab

Administration: 10 mg/kg IV every 4 weeks. t_1/2: ~15 days. Clearance: Hepatic and renal pathways; dose adjustments may be necessary in severe impairment.

Therapeutic Uses/Clinical Applications

Cholinesterase Inhibitors

Approved indications encompass mild to moderate AD, with rivastigmine also approved for mild to moderate Parkinson’s disease dementia. Symptomatic benefits include modest improvements in cognition, behavior, and activities of daily living (ADL). The therapeutic response is generally transient, with benefits diminishing as disease progresses.

Memantine

Indicated for moderate to severe AD. When combined with a ChEI, memantine offers additive benefits in cognition and global function. The drug is often introduced after 6–12 months of symptomatic therapy or at the onset of moderate disease.

Amyloid‑β Antibodies

Aducanumab, lecanemab, and donanemab are approved for mild to moderate AD with measurable amyloid pathology. These agents aim to reduce amyloid burden and slow cognitive decline. Regular monitoring via PET imaging and cognitive scales is recommended to assess efficacy and detect adverse events.

Off‑Label and Emerging Uses

Rivastigmine has been used off‑label for vascular dementia, although evidence is limited. Memantine is occasionally prescribed for agitation or behavioral disturbances in advanced AD. Investigational agents may target tau pathology or neuroinflammation, but clinical application remains experimental.

Adverse Effects

Cholinesterase Inhibitors

Common side effects include nausea, vomiting, anorexia, diarrhea, and insomnia. These gastrointestinal events are dose‑dependent and often resolve with titration. Bradycardia and syncope may occur, particularly in patients with pre‑existing conduction abnormalities. Rarely, severe cholinergic crisis can manifest as muscle weakness or respiratory depression.

Memantine

Adverse reactions are infrequent but may involve dizziness, headache, confusion, and constipation. In rare instances, neuropsychiatric symptoms such as hallucinations or agitation have been reported.

Amyloid‑β Antibodies

The principal safety concern is amyloid‑related imaging abnormalities (ARIA), encompassing vasogenic edema (ARIA‑E) and microhemorrhage (ARIA‑H). ARIA may present with headache, confusion, seizures, or focal neurological deficits. Routine MRI screening before and during therapy is recommended. Infusion reactions, including hypersensitivity, can occur during IV administration. Other systemic effects include hypertension, rash, and transient elevations in liver enzymes.

Black Box Warnings

All amyloid‑targeting monoclonal antibodies carry a black box warning for ARIA. Clinicians must be vigilant for neurological symptoms and promptly evaluate with neuroimaging. Cholinesterase inhibitors are not associated with black box warnings; however, severe bradyarrhythmias warrant caution.

Drug Interactions

Cholinesterase Inhibitors

Donepezil: Potential interaction with CYP2D6 inhibitors (e.g., fluoxetine) may increase plasma concentrations, heightening adverse effects. Rivastigmine: CYP3A4 inhibitors (e.g., ketoconazole) may elevate levels, whereas CYP3A4 inducers (e.g., rifampin) can reduce efficacy. Galantamine: Strong CYP2D6 inhibitors can raise galantamine exposure; concurrent use with drugs causing bradycardia (e.g., beta‑blockers) may exacerbate cardiac effects.

Memantine

Minimal drug interactions due to limited hepatic metabolism. Caution is advised when combined with other CNS depressants (e.g., benzodiazepines) due to additive sedation.

Amyloid‑β Antibodies

No significant pharmacokinetic interactions are known, given the monoclonal antibody structure. However, concomitant use of anticoagulants or antiplatelet agents may increase the risk of ARIA‑H. Careful monitoring is essential.

Contraindications

Cholinesterase inhibitors: Severe cardiac conduction abnormalities, uncontrolled arrhythmias, or significant gastrointestinal obstruction. Memantine: Severe hepatic impairment (Child‑Pugh C) due to uncertain safety profile. Amyloid‑targeting antibodies: Active systemic infection, uncontrolled hypertension, or recent intracranial hemorrhage.

Special Considerations

Pregnancy and Lactation

Data are limited; however, animal studies suggest potential teratogenicity for ChEIs. Consequently, these agents are generally contraindicated during pregnancy. Breastfeeding is discouraged due to possible drug transfer via milk. Amyloid‑β antibodies lack sufficient human data; the risk of fetal exposure via IV infusion is considered low but remains unstudied.

Pediatric Considerations

AD therapeutics are not approved for pediatric use. Off‑label prescribing is rare and should be confined to clinical trials or compassionate use programs, with careful monitoring for developmental toxicity.

Geriatric Considerations

Elderly patients often present with polypharmacy, frailty, and comorbidities. Dose titration should proceed cautiously, particularly for ChEIs, to minimize gastrointestinal and cardiac adverse events. Memantine’s long half‑life may lead to accumulation in renal impairment; dose adjustment is advised for creatinine clearance <30 mL/min.

Renal and Hepatic Impairment

Donepezil: Minor dose adjustment for severe hepatic dysfunction; renal clearance is unaffected. Rivastigmine: Dose reduction recommended in severe renal impairment; transdermal patch offers a safer alternative. Galantamine: Adjust dose in moderate renal impairment; monitor for accumulation. Memantine: Renal excretion necessitates dose reduction in creatinine clearance <30 mL/min. Amyloid‑β antibodies: Renal and hepatic impairment may alter clearance; dose adjustments should be guided by clinical judgment and laboratory parameters.

Summary/Key Points

• Symptomatic therapy for AD primarily involves cholinesterase inhibitors and the NMDA antagonist memantine; disease‑modifying agents target amyloid pathology.
• ChEIs enhance synaptic acetylcholine by reversible or irreversible inhibition of AChE, while memantine attenuates glutamate‑induced excitotoxicity.
• Pharmacokinetic profiles differ markedly: ChEIs exhibit moderate bioavailability and hepatic metabolism; memantine is renally cleared; monoclonal antibodies rely on proteolytic pathways.
• Adverse effects range from mild gastrointestinal upset to serious ARIA with amyloid‑targeting antibodies; black box warnings necessitate vigilant monitoring.
• Drug interactions are primarily mediated through cytochrome P450 enzymes for ChEIs; monoclonal antibodies have minimal pharmacokinetic interactions.
• Special populations—including pregnant women, the elderly, and patients with renal or hepatic impairment—require individualized dosing strategies and careful surveillance.
• Ongoing clinical trials and emerging therapeutics underscore the dynamic nature of AD pharmacotherapy; staying current with evidence is paramount for optimal patient care.

Clinicians should integrate pharmacologic knowledge with patient‑specific factors to formulate comprehensive, individualized treatment plans for individuals affected by Alzheimer’s disease.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.